Higher ViP signatures in MIS-C tracked three major clinical and/or laboratory parameters (see Fig. 7b): (i) degree of thrombocytopenia in severe cases (all three diseases); (ii) eosinopenia (in COVID-19 and MIS-C, but not KD) and (iii) impaired cardiac contractility (unique to MIS-C; but not KD); (iii) an integrated analysis of serum cytokines and transcriptomics revealed that the proinflammatory MIP1α, TNFα, and IL1 pathways are significantly induced in MIS-C compared to KD. The gene discussed is IL1B; the disease is COVID-19.